KFDA approved second indication for Cozaar.

Published: 2003-04-07 06:57:00

Updated: 2003-04-07 06:57:00

The KFDA approved Cozaar, an anti-hypertensive drug (Losartan K) of MSD Korea for the treatment of renopathy complicated with the type 2 diabetic patient as the 2nd indication.

The KFDA's approval was based on the study article titled "Reduction of Endpoints in NIDDM with the Angiotensin II an...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK